Karyopharm Therapeutics (KPTI) Non-Current Deffered Revenue (2014 - 2020)

Karyopharm Therapeutics has reported Non-Current Deffered Revenue for 7 years, with the latest figure at $2.2 million in Q1 2020.

• For the quarter ending Q1 2020, Non-Current Deffered Revenue fell 32.45% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2020 stood at $2.2 million (down 32.45% YoY), and the FY2019 full-year result was $2.2 million, down 51.63% from the prior year.
• Non-Current Deffered Revenue for Q1 2020 stood at $2.2 million, roughly flat from $2.2 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $4.5 million in Q2 2018, with the low at $1.4 million in Q4 2017.
• Historically, Non-Current Deffered Revenue has averaged $2.4 million across 5 years, with a median of $1.9 million in 2018.
• Annual changes were most pronounced in 2018 — Non-Current Deffered Revenue soared 232.5% — and 2019, when it plunged 51.63%.
• Karyopharm Therapeutics' Non-Current Deffered Revenue stood at $1.7 million in 2016, then retreated by 18.19% to $1.4 million in 2017, then soared by 232.5% to $4.5 million in 2018, then sank by 51.63% to $2.2 million in 2019, then changed by 0.0% to $2.2 million in 2020.
• The last three Non-Current Deffered Revenue figures came in at $2.2 million (Q1 2020), $2.2 million (Q4 2019), and $3.5 million (Q3 2019), per Business Quant data.